301 results about "High risk group" patented technology

The present invention offers a comprehensive solution to care management which aggregates, integrates and stores clinical information from disparate sources. The system finds at-risk individuals before they experience preventable, high-cost medical events and stratifies high risk populations according to clinical criteria, which can include severity of disease states and co-morbidities. The system also compares the actual care an individual is receiving to established standards of clinical excellence and, if necessary, suggests pertinent medical care considerations to improve the care of medically mismanaged individuals. Another feature of the present invention may include a secure, patient-specific Web page which is automatically populated with a patient's own clinical information and can be personalized with customized, relevant healthcare information. The system allows users to design, facilitate and monitor clinical care plans and increase communications among physicians, nurses and patients. The system also predicts and analyzes the outcome of disease or case management for populations and individual patients.

The invention relates to a method and a kit for diagnosing bladder cancer with urine. The invention discloses a group of methylated sensitive genes, comprising ECEL1, KCNV1, LMX1A, PROX1, SLC6A20, TAL1, TMEM 26, and VAXI gene. In urine samples of bladder cancer patients, the specific CpG sites of the genes are showed the highest methylation levels. Accordingly, the genes are the biological marker of bladder cancer. The method and the kit can be used as the basic of designing diagnostic reagents of bladder cancer, and are suitable for auxiliary detection of cancer in hospitals, postoperative followup, screening of high risk group of bladder cancer in community health centers, and screening of common people and high risk practitioners of bladder cancer in physical examination center.

The invention belongs to the technical field of rehabilitation medicine protection and particularly relates to a method for evaluating the balance capacity of old people. The method includes the following steps that A, experimental subjects are grouped into a normal group, a low-risk group, a middle-risk group and a high-risk group according an old people balance capacity test scale, plantar pressure distribution generated when the old people sit up is detected through a plantar pressure distribution detecting system, and cushion pressure generated when the old people sit up is detected through a cushion sensor; B, the old people walk on a three-dimensional dynamometry table, and kinematics parameters of the gaits generated when the old people walk are acquired through the three-dimensional dynamometry table, wherein the kinematics parameters comprise the pressure and torque in the foot vertical direction, the pressure and torque in the foot front-and-back direction and the pressure and torque in the foot inside and outside directions; C, sample entropies of the plantar pressure and torque during sitting up and walking are subjected to statistic analysis, the significant difference of the correlativity between the variable sample entropies is found, and an objective evaluation standard is obtained. The method has the advantage of being capable of evaluating dynamic balance of the old people.

The invention relates to a kit for detecting susceptibility gene SNP locus of nasopharynx cancer, which is realized through the steps as follows: detecting a PCR amplimer and a single-base extension primer of an SNP locus rs2860580 of a susceptibility gene CDKN2A-CDKN2B of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs1572072 and rs9510787 of a susceptibility gene TNFRSF19 area of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs28421666,rs2860580 and rs2894207 of a susceptibility gene HLA of nasopharynx cancer; and detecting a PCR amplimer and a single-base extension primer of an SNP locus rs6774494 of a susceptibility gene MDS1-EVI1 of nasopharynx cancer. The kit provided by the invention can be used for simultaneously detecting the SNP loci of a plurality of susceptibility genes of nasopharynx cancer, and provides reference for estimating risk degree of individuals affected by nasopharynx cancer, general survey of populations with high nasopharynx cancer incidence, screening of high risk group attacked by nasopharynx cancer and implementation of relative precautionary measures.

The invention provides a chronic kidney disease screening method and system, and particularly relates to a machine learning method for constructing a chronic kidney disease screening model, which comprises the steps of establishing an effective chronic kidney disease screening model, arranging user data to be screened, substituting the user data to be screened into the chronic kidney disease screening model for model calculation, and finally obtaining a kidney disease risk result. Therefore, the chronic kidney disease screening system is efficient, low in cost and high in accuracy. According to the method, a machine learning BP neural network, XGBoost and a random forest integration algorithm are adopted to train a chronic kidney disease screening model; high-risk groups with chronic kidney diseases can be automatically screened out according to basic body measurement information, symptom information, medical examination information, family history, past history, living habits and other data, and the accuracy reaches up to 0.96 or above.

The invention discloses an application method of serum Exosomes derived long no-coding RNA (long no-coding RNA, LncRNA) LINC00470, namely, serum Exosomes derived long no-coding RNA LINC00470 is used for preparing prognosis preparations for the screening and early diagnosis of high-risk groups with glioma and patients with glioma. Reaches prove that RNA is extracted after Exosomes are separated from serums of patients with glioma, and through carrying out reverse transcription and real-time fluorescent quantitative analysis on the RNA, a situation that the expression level of LncRNA LINC00470 is lowered is found. According to the invention, the specificity of the serum Exosomes LncRNA LINC00470 to the early diagnosis of glioma can reach 85.7%, and the sensitivity can reach 94.1%. By testing the expression level of LncRNA LINC00470 in serum Exosomes of patients with glioma, an early and rapid noninvasive diagnosis on the patients with glioma is implemented.